Pulmonx Corporation (LUNG)

NMS – Цена в реальном времени. Валюта: USD

1.29

-0.01 (-0.77%)

При закрытии: May 12, 2026, 4:00 PM EDT

1.29

0.00 (0.00%)

До открытия: May 13, 2026, 4:00 AM EDT

12.05.2026

Pulmonx Corporation (LUNG) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

30.04.2026

Pulmonx Corporation (LUNG) Q1 2026 Earnings Call Transcript

29.04.2026

Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates

Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.33 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.36 per share a year ago.

29.04.2026

Pulmonx Reports First Quarter 2026 Financial Results

REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2026 ended March 31, 2026.

28.04.2026

Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference

REDWOOD CITY, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America Securities 2026 Health Care Conference in Las Vegas on Tuesday, May 12, 2026, at 8:15 AM PT / 11:15 AM ET.

15.04.2026

Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026

REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2026 after the close of trading on Wednesday, April 29, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

04.03.2026

Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates

Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.33 per share a year ago.

Видео

No Data

There is no data to display

Пресс-релизы

29.04.2026

Pulmonx Reports First Quarter 2026 Financial Results

04.03.2026

Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results

REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2025.

04.03.2026

Pulmonx Announces Closing of up to $60 Million Credit Facility

Refinancing Strengthens Capital Structure by Extending Debt Maturity and Providing Access to Additional Undrawn Capital Refinancing Strengthens Capital Structure by Extending Debt Maturity and Providing Access to Additional Undrawn Capital

03.12.2025

Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on December 1, 2025 (the “Grant Date”), Pulmonx granted equity awards under its 2025 Inducement Plan (the “Inducement Plan”) for an aggregate of 1,625,000 shares of Pulmonx's common stock to two individuals hired by Pulmonx in the fourth quarter of 2025, including Pulmonx's Chief Financial Officer and Chief Operating Officer, Derrick Sung. The awards were approved by the Compensation Committee of the Company's Board of Directors and were granted as an inducement material to the new employees entering into employment with Pulmonx, in accordance with Nasdaq Listing Rule 5635(c)(4). Each award is subject to the terms and conditions of the Inducement Plan and the grant agreements covering the awards.

Pulmonx Corporation (LUNG)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Pulmonx Corporation (LUNG)

Pulmonx Corporation (LUNG) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

Pulmonx Corporation (LUNG) Q1 2026 Earnings Call Transcript

Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates

Pulmonx Reports First Quarter 2026 Financial Results

Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference

Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026

Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates

Видео

No Data

Пресс-релизы

Pulmonx Reports First Quarter 2026 Financial Results

Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results

Pulmonx Announces Closing of up to $60 Million Credit Facility

Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Pulmonx Corporation (LUNG) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

Pulmonx Corporation (LUNG) Q1 2026 Earnings Call Transcript

Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates

Pulmonx Reports First Quarter 2026 Financial Results

Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference

Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026

Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates

Видео

No Data

Пресс-релизы

Pulmonx Reports First Quarter 2026 Financial Results

Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results

Pulmonx Announces Closing of up to $60 Million Credit Facility

Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Search stocks

Pulmonx Corporation (LUNG)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Pulmonx Corporation (LUNG)

Pulmonx Corporation (LUNG) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

Pulmonx Corporation (LUNG) Q1 2026 Earnings Call Transcript

Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates

Pulmonx Reports First Quarter 2026 Financial Results

Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference

Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026

Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates

Видео

No Data

Пресс-релизы

Pulmonx Reports First Quarter 2026 Financial Results

Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results

Pulmonx Announces Closing of up to $60 Million Credit Facility

Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Pulmonx Corporation (LUNG) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

Pulmonx Corporation (LUNG) Q1 2026 Earnings Call Transcript

Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates

Pulmonx Reports First Quarter 2026 Financial Results

Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference

Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026

Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates

Видео

No Data

Пресс-релизы

Pulmonx Reports First Quarter 2026 Financial Results

Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results

Pulmonx Announces Closing of up to $60 Million Credit Facility

Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)